贝伐单抗联合FOLFOX4方案治疗晚期结直肠癌的临床疗效观察  

The clinical efficacy of bevacizumab in combination with FOLFOX4 regimen in the treatment of advanced colorectal cancer

作　　者：韩志军[1] 

机构地区：[1]唐山市丰润区人民医院,河北唐山064000

出　　处：《结直肠肛门外科》2015年第1期35-38,共4页Journal of Colorectal & Anal Surgery

摘　　要：目的观察贝伐单抗联合FOLFOX4方案治疗晚期结直肠癌的临床疗效与安全性。方法 2007年7月至2011年7月期间我院收治的晚期结直肠癌患者87例,按照其治疗方案分为实验组（42例）和对照组（45例）。实验组接受贝伐单抗＋FOLFOX4方案治疗,对照组只接受FOLFOX4方案治疗,比较两组患者的近期疗效、远期疗效及不良反应。结果实验组和对照组有效率分别为40.5%和17.8%（χ^2=5.466,P〈0.05）,差异有统计学意义;疾病控制率分别为71.4%和44.4%（χ^2=6.472,P〈0.05）,差异有统计学意义。两组远期疗效比较,实验组的中位总生存期和中位无进展生存期分别为15.6个月和8.9个月,明显优于对照组的10.6个月和5.8个月,差异均有统计学意义（P〈0.05）。两组患者不良反应多为I～Ⅱ级,差异无统计学意义（P〉0.05）。结论贝伐单抗联合FOLFOX4方案治疗晚期结直肠癌患者效果优于单用FOLFOX4方案治疗,而且患者不良反应无明显增加。Objective To explore the efficacy and safety of advanced colorectal cancer patients treated by bevacizumab combined FOLFOX4 regimen.Methods Eighty-seven patients with advanced colorectal cancer were divided into bevacizumab combined FOLFOX4 regimen group（the study group,N =42）and FOLFOX4 regimen group（the control group,N =45）according to the treatment program.The efficacy,side effects and survival time in two groups were observed and compared.Results The objective response rate（ORR）of the study and control group was 40.5% and 17.8%,respectively.The disease control rate（DCR）of the two groups was 71.4% and 44.4%,respectively,and the difference were all statistically significant（P〈0.05）.The median disease free survival（DFS）of bevacizumab combined FOLFOX4 regimen group and FOLFOX4 regimen group was 8.9and 5.8months,respectively;The median overall survival（OS）of the two groups was 15.6and 10.6months,respectively,and the difference were all statistically significant（P〈0.05）.The side effects in two groups include diarrhea and gastrointestinal reactions,but all were grade I～Ⅱ.Conclusion The efficacy of bevacizumab combined FOLFOX4 regimen in treatment of patients with advanced colorectal cancer is reliable.It can increase the response rate and prolong median overall survival time with low side effects.

关 键 词：贝伐单抗 FOLFOX4方案 晚期结直肠癌 

分 类 号：R735.34[医药卫生—肿瘤]